Open Access Articles- Top Results for Cabazitaxel


Systematic (IUPAC) name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[,10.04,7]heptadec-13-ene-2-yl benzoate
Clinical data
Trade names Jevtana
AHFS/ Consumer Drug Information
MedlinePlus a611009
Licence data EMA:Link, US FDA:link
  • US: D (Evidence of risk)
183133-96-2 7pxN
PubChem CID 9854073
DrugBank DB06772 7pxY
ChemSpider 8029779 7pxY
UNII 51F690397J 7pxY
ChEBI CHEBI:63584 7pxN
ChEMBL CHEMBL1201748 7pxN
Chemical data
Formula C45H57NO14
835.93 g/mol
 14pxN (what is this?)  (verify)

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.[1] It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[2][unreliable source?]

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.

Clinical trials

In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%).[3]


External links

Lua error in package.lua at line 80: module 'Module:Buffer' not found.